Skip to main content
Top
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Cervical Cancer | Research

Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women

Authors: Sara Bønløkke, Jan Blaakær, Torben Steiniche, Maria Iachina

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

Background

For cervical cancer (CC), the implementation of preventive strategies has the potential to make cervical cancer occurrence and death largely avoidable. To better understand the factors possibly responsible for cervical cancer, we aimed to examine possible differences in age and social parameters as well as screening status between women with low- or high-stage cervical cancer and matched controls.

Methods

Through the Danish Cancer Registry (DCR), women diagnosed with cervical cancer in Denmark between 1987 and 2016 were included. These were age- and residence-matched in a 1:5 ratio with controls from the general female population. The study population was sub grouped into a low-stage subpopulation with women with early-stage cervical cancer and matched controls and a high-stage subpopulation with women with late-stage cervical cancer and matched controls. Age and social parameters were compared within the subpopulations as well as between low- and high-stage cases. For part of the study population, screening attendance was examined to compare differences in adherence.

Results

Overall, we found that the risk of cervical cancer is significantly increased in socially disadvantaged women and not least non-attenders in screening. Interestingly, the high-stage subpopulation was significantly older than the low-stage subpopulation (p < 0.001), and when examining the impact of age further, we found that for cervical cancer cases, the risk of having low-stage disease decreases significantly with increasing age, whereas the risk of having high-stage disease increases significantly with increasing age. In the screening cohort, significantly less cases than controls were attenders in screening with the most pronounced differences seen in the old subpopulation (women aged 50–64 years) and in the high-stage subpopulation (p-values all < 0.001). Interestingly, when examining the risk of CC for attenders and non-attenders, we demonstrated that many social parameters continue to influence the risk of cervical cancer, even in women attending screening.

Conclusions

Older women, socially disadvantaged women, and non-attenders in screening are particularly vulnerable in terms of developing cervical cancer, especially high-stage disease. Therefore, improvements in the participating rate in screening as well as a revision of the current screening guidelines are needed.
Appendix
Available only for authorised users
Literature
1.
go back to reference Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRef Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.PubMedCrossRef
2.
go back to reference WHO. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Human papillomaviruses. World Health Organization; 2007. WHO. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 90. Human papillomaviruses. World Health Organization; 2007.
5.
go back to reference Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.PubMedPubMedCentralCrossRef Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497–509.PubMedPubMedCentralCrossRef
6.
go back to reference Australian Institute of Health and Welfare. Cervical screening in Australia 2011–2012. Cancer series no82 Cat no CAN 79. 2014. Australian Institute of Health and Welfare. Cervical screening in Australia 2011–2012. Cancer series no82 Cat no CAN 79. 2014.
7.
go back to reference Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the Quadrivalent Human Papillomavirus Vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27.PubMedPubMedCentralCrossRef Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and effectiveness of the Quadrivalent Human Papillomavirus Vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27.PubMedPubMedCentralCrossRef
8.
go back to reference Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340–8.PubMedCrossRef Lei J, Ploner A, Elfstrom KM, Wang J, Roth A, Fang F, et al. HPV Vaccination and the risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340–8.PubMedCrossRef
9.
go back to reference Arbyn M, Weiderpass E, Capocaccia R. Effect of screening on deaths from cervical cancer in Sweden. BMJ. 2012;344:e804.PubMedCrossRef Arbyn M, Weiderpass E, Capocaccia R. Effect of screening on deaths from cervical cancer in Sweden. BMJ. 2012;344:e804.PubMedCrossRef
10.
go back to reference van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer. 2008;122(8):1854–8.PubMedCrossRef van der Aa MA, Pukkala E, Coebergh JW, Anttila A, Siesling S. Mass screening programmes and trends in cervical cancer in Finland and the Netherlands. Int J Cancer. 2008;122(8):1854–8.PubMedCrossRef
11.
go back to reference Aareleid T, Pukkala E, Thomson H, Hakama M. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population. Eur J Cancer. 1993;29A(5):745–9.PubMedCrossRef Aareleid T, Pukkala E, Thomson H, Hakama M. Cervical cancer incidence and mortality trends in Finland and Estonia: a screened vs. an unscreened population. Eur J Cancer. 1993;29A(5):745–9.PubMedCrossRef
12.
go back to reference Adami HO, Ponten J, Sparen P, Bergstrom R, Gustafsson L, Friberg LG. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. 1960–1984. Cancer. 1994;73(1):140–7.PubMedCrossRef Adami HO, Ponten J, Sparen P, Bergstrom R, Gustafsson L, Friberg LG. Survival trend after invasive cervical cancer diagnosis in Sweden before and after cytologic screening. 1960–1984. Cancer. 1994;73(1):140–7.PubMedCrossRef
13.
go back to reference D’Alo D, Stracci F, Cassetti T, Scheibel M, Pascucci C, La Rosa F. Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978–2005. Eur J Gynaecol Oncol. 2010;31(2):174– 80. D’Alo D, Stracci F, Cassetti T, Scheibel M, Pascucci C, La Rosa F. Recent trends in incidence, mortality and survival after cancer of the female breast and reproductive organs. Umbria, Italy: 1978–2005. Eur J Gynaecol Oncol. 2010;31(2):174– 80.
14.
go back to reference Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100(9):622–9.PubMedCrossRef Andrae B, Kemetli L, Sparen P, Silfverdal L, Strander B, Ryd W, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100(9):622–9.PubMedCrossRef
15.
go back to reference Anttila A, Nieminen P. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Coll Antropol. 2007;31(Suppl 2):17–22.PubMed Anttila A, Nieminen P. Cervical cancer screening programme in Finland with an example on implementing alternative screening methods. Coll Antropol. 2007;31(Suppl 2):17–22.PubMed
16.
go back to reference Bigaard J, Hariri J, Lynge E. Cervical cancer screening in Denmark. Eur J Cancer. 2000;36(17):2198–204.PubMedCrossRef Bigaard J, Hariri J, Lynge E. Cervical cancer screening in Denmark. Eur J Cancer. 2000;36(17):2198–204.PubMedCrossRef
18.
go back to reference Danckert BFJ, Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt LKH, Virtanen A, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries Danish Cancer Society http://wwwancrnu, Accessed 19 January 2023. Danckert BFJ, Engholm G, Hansen HL, Johannesen TB, Khan S, Køtlum JE, Ólafsdóttir E, Schmidt LKH, Virtanen A, Storm HH. NORDCAN: Cancer Incidence, Mortality, Prevalence and Survival in the Nordic Countries, Version 8.2 (26.03.2019). Association of the Nordic Cancer Registries Danish Cancer Society http://​wwwancrnu, Accessed 19 January 2023.
20.
go back to reference Baldur-Felskov B, Munk C, Nielsen TS, Dehlendorff C, Kirschner B, Junge J, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control. 2015;26(8):1105–16.PubMedCrossRef Baldur-Felskov B, Munk C, Nielsen TS, Dehlendorff C, Kirschner B, Junge J, et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control. 2015;26(8):1105–16.PubMedCrossRef
21.
go back to reference Hammer A, Kahlert J, Rositch A, Pedersen L, Gravitt P, Blaakaer J, et al. The temporal and age-dependent patterns of hysterectomy-corrected cervical cancer incidence rates in Denmark: a population-based cohort study. Acta Obstet Gynecol Scand. 2017;96(2):150–7.PubMedCrossRef Hammer A, Kahlert J, Rositch A, Pedersen L, Gravitt P, Blaakaer J, et al. The temporal and age-dependent patterns of hysterectomy-corrected cervical cancer incidence rates in Denmark: a population-based cohort study. Acta Obstet Gynecol Scand. 2017;96(2):150–7.PubMedCrossRef
23.
go back to reference Kreusch T, Wang J, Sparen P, Sundstrom K. Opportunistic HPV vaccination at age 16–23 and cervical screening attendance in Sweden: a national register-based cohort study. Bmj Open. 2018;8(10). Kreusch T, Wang J, Sparen P, Sundstrom K. Opportunistic HPV vaccination at age 16–23 and cervical screening attendance in Sweden: a national register-based cohort study. Bmj Open. 2018;8(10).
24.
go back to reference Boone SD, Pinkston CM, Baumgartner KB, Baumgartner RN, Harper SM, Bonham AJ, et al. Associations between prior HPV4 vaccine doses and cervical cancer screening participation. Cancer Epidemiol. 2016;42:108–14.PubMedCrossRef Boone SD, Pinkston CM, Baumgartner KB, Baumgartner RN, Harper SM, Bonham AJ, et al. Associations between prior HPV4 vaccine doses and cervical cancer screening participation. Cancer Epidemiol. 2016;42:108–14.PubMedCrossRef
25.
go back to reference Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data. Brit J Cancer. 2016;114(5):576–81.PubMedPubMedCentralCrossRef Palmer TJ, McFadden M, Pollock KGJ, Kavanagh K, Cuschieri K, Cruickshank M, et al. HPV immunisation and increased uptake of cervical screening in Scottish women; observational study of routinely collected national data. Brit J Cancer. 2016;114(5):576–81.PubMedPubMedCentralCrossRef
26.
go back to reference Chao C, Silverberg MJ, Becerra TA, Corley DA, Jensen CD, Chen QL et al. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. Am J Obstet Gynecol. 2017;216(2). Chao C, Silverberg MJ, Becerra TA, Corley DA, Jensen CD, Chen QL et al. Human papillomavirus vaccination and subsequent cervical cancer screening in a large integrated healthcare system. Am J Obstet Gynecol. 2017;216(2).
27.
go back to reference Kim J, Bell C, Sun MG, Kliewer G, Xu LA, McInerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Can Med Assoc J. 2016;188(12):E281–E8.CrossRef Kim J, Bell C, Sun MG, Kliewer G, Xu LA, McInerney M, et al. Effect of human papillomavirus vaccination on cervical cancer screening in Alberta. Can Med Assoc J. 2016;188(12):E281–E8.CrossRef
28.
go back to reference Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlstrom L, Uhnoo I, Netterlid E et al. The participation of HPV-Vaccinated women in a National Cervical Screening Program: Population-based Cohort Study. PLoS ONE. 2015;10(7). Herweijer E, Feldman AL, Ploner A, Arnheim-Dahlstrom L, Uhnoo I, Netterlid E et al. The participation of HPV-Vaccinated women in a National Cervical Screening Program: Population-based Cohort Study. PLoS ONE. 2015;10(7).
29.
go back to reference Paynter CA, Van Treeck BJ, Verdenius I, Lau AW, Dhawan T, Lash KA, et al. Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. Prev Med Rep. 2015;2:711–6.PubMedPubMedCentralCrossRef Paynter CA, Van Treeck BJ, Verdenius I, Lau AW, Dhawan T, Lash KA, et al. Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. Prev Med Rep. 2015;2:711–6.PubMedPubMedCentralCrossRef
30.
go back to reference Sauer AG, Jemal A, Simard EP, Fedewa SA. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008–2013. Cancer Epidemiol. 2015;39(4):650–5.PubMedCrossRef Sauer AG, Jemal A, Simard EP, Fedewa SA. Differential uptake of recent Papanicolaou testing by HPV vaccination status among young women in the United States, 2008–2013. Cancer Epidemiol. 2015;39(4):650–5.PubMedCrossRef
31.
go back to reference Kliewer EV, Mahmud SM, Demers AA, Lambert P. Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. Vaccine. 2013;32(1):33–8.PubMedCrossRef Kliewer EV, Mahmud SM, Demers AA, Lambert P. Human papillomavirus vaccination and Pap testing profile in Manitoba, Canada. Vaccine. 2013;32(1):33–8.PubMedCrossRef
32.
go back to reference Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? Vaccine. 2014;32(16):1828–33.PubMedPubMedCentralCrossRef Beer H, Hibbitts S, Brophy S, Rahman MA, Waller J, Paranjothy S. Does the HPV vaccination programme have implications for cervical screening programmes in the UK? Vaccine. 2014;32(16):1828–33.PubMedPubMedCentralCrossRef
33.
go back to reference Badre-Esfahani S, Larsen MB, Seibaek L, Petersen LK, Blaakaer J, Stovring H, et al. Non-adherence to childhood HPV vaccination is Associated with Non-participation in Cervical Cancer screening - A nationwide Danish Register-based Cohort Study. Clin Epidemiol. 2019;11:969–80.PubMedPubMedCentralCrossRef Badre-Esfahani S, Larsen MB, Seibaek L, Petersen LK, Blaakaer J, Stovring H, et al. Non-adherence to childhood HPV vaccination is Associated with Non-participation in Cervical Cancer screening - A nationwide Danish Register-based Cohort Study. Clin Epidemiol. 2019;11:969–80.PubMedPubMedCentralCrossRef
34.
go back to reference Kirschner B, Poll S, Rygaard C, Wahlin A, Junge J. Screening history in women with cervical cancer in a Danish population-based screening program. Gynecol Oncol. 2011;120(1):68–72.PubMedCrossRef Kirschner B, Poll S, Rygaard C, Wahlin A, Junge J. Screening history in women with cervical cancer in a Danish population-based screening program. Gynecol Oncol. 2011;120(1):68–72.PubMedCrossRef
35.
go back to reference Boulanger JC, Fauvet R, Urrutiaguer S, Drean Y, Sevestre H, Ganry O, et al. Cytological history of cases of invasive cervical cancer diagnosed in France in 2006. Gynecol Obstet Ferti. 2007;35(9):764–71.CrossRef Boulanger JC, Fauvet R, Urrutiaguer S, Drean Y, Sevestre H, Ganry O, et al. Cytological history of cases of invasive cervical cancer diagnosed in France in 2006. Gynecol Obstet Ferti. 2007;35(9):764–71.CrossRef
36.
go back to reference Nygard JF, Nygard M, Skare GB, Thoresen SO. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian coordinated cervical Cancer Screening Program. Cancer Causes Control. 2005;16(4):463–74.PubMedCrossRef Nygard JF, Nygard M, Skare GB, Thoresen SO. Screening histories of women with CIN 2/3 compared with women diagnosed with invasive cervical cancer: a retrospective analysis of the Norwegian coordinated cervical Cancer Screening Program. Cancer Causes Control. 2005;16(4):463–74.PubMedCrossRef
37.
go back to reference Fritz APC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva: WHO;; 2000. Fritz APC, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S. International classification of diseases for oncology (ICD-O). 3rd ed. Geneva: WHO;; 2000.
38.
go back to reference Pedersen CB. The Danish Civil Registration System. Scand J Public Healt. 2011;39:22–5.CrossRef Pedersen CB. The Danish Civil Registration System. Scand J Public Healt. 2011;39:22–5.CrossRef
39.
go back to reference Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–89.PubMedPubMedCentralCrossRef Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–89.PubMedPubMedCentralCrossRef
40.
go back to reference Gjerstorff ML. The Danish Cancer Registry. Scand J Public Healt. 2011;39:42–5.CrossRef Gjerstorff ML. The Danish Cancer Registry. Scand J Public Healt. 2011;39:42–5.CrossRef
41.
go back to reference Rothman K. Modern epidemiology. Boston: Little, Brown and Company; 1986. Rothman K. Modern epidemiology. Boston: Little, Brown and Company; 1986.
42.
go back to reference Charlson ME, Pompei P, Ales KL, Mackenzie CR. A New Method of classifying Prognostic Co-morbidity in Longitudinal-Studies - Development and Validation. J Chron Dis. 1987;40(5):373–83.PubMedCrossRef Charlson ME, Pompei P, Ales KL, Mackenzie CR. A New Method of classifying Prognostic Co-morbidity in Longitudinal-Studies - Development and Validation. J Chron Dis. 1987;40(5):373–83.PubMedCrossRef
43.
go back to reference Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Healt. 2011;39:30–3.CrossRef Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Healt. 2011;39:30–3.CrossRef
44.
go back to reference Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7 Suppl):103–5.PubMedCrossRef Baadsgaard M, Quitzau J. Danish registers on personal income and transfer payments. Scand J Public Health. 2011;39(7 Suppl):103–5.PubMedCrossRef
45.
go back to reference Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7 Suppl):91–4.PubMedCrossRef Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39(7 Suppl):91–4.PubMedCrossRef
46.
go back to reference Noordhoek JAP, Ole K. Jan. Household and Family Concepts in Danish Population Registers and Surveys. 1984;1 1984: 169–178. Noordhoek JAP, Ole K. Jan. Household and Family Concepts in Danish Population Registers and Surveys. 1984;1 1984: 169–178.
49.
go back to reference Quinn M, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet. 2006;95:43–S103.CrossRef Quinn M, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, et al. Carcinoma of the cervix uteri. Int J Gynecol Obstet. 2006;95:43–S103.CrossRef
50.
go back to reference Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43-103. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S43-103.
52.
go back to reference Ibfelt E, Kjaer SK, Johansen C, Hogdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic position and stage of cervical Cancer in Danish women diagnosed 2005 to 2009. Cancer Epidem Biomar. 2012;21(5):835–42.CrossRef Ibfelt E, Kjaer SK, Johansen C, Hogdall C, Steding-Jessen M, Frederiksen K, et al. Socioeconomic position and stage of cervical Cancer in Danish women diagnosed 2005 to 2009. Cancer Epidem Biomar. 2012;21(5):835–42.CrossRef
53.
go back to reference Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev. 2003;12(3):242s–7s.PubMed Garner EI. Cervical cancer: disparities in screening, treatment, and survival. Cancer Epidemiol Biomarkers Prev. 2003;12(3):242s–7s.PubMed
54.
go back to reference Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer. 2007;31(3):157–81.PubMedCrossRef Akers AY, Newmann SJ, Smith JS. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. Curr Probl Cancer. 2007;31(3):157–81.PubMedCrossRef
55.
go back to reference Ingemann-Hansen O, Lidang M, Niemann I, Dinesen J, Baandrup U, Svanholm H, et al. Screening history of women with cervical cancer: a 6-year study in Aarhus, Denmark. Brit J Cancer. 2008;98(7):1292–4.PubMedPubMedCentralCrossRef Ingemann-Hansen O, Lidang M, Niemann I, Dinesen J, Baandrup U, Svanholm H, et al. Screening history of women with cervical cancer: a 6-year study in Aarhus, Denmark. Brit J Cancer. 2008;98(7):1292–4.PubMedPubMedCentralCrossRef
56.
go back to reference Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45(2–3):93–106.PubMedCrossRef Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45(2–3):93–106.PubMedCrossRef
57.
go back to reference Lopez-de-Andres A, Martin-Lopez R, Hernandez-Barrera V, Carrasco-Garrido P, Gil-de-Miguel A, Pena MMEY, et al. Predictors of breast and cervical Cancer screening in a Spanish Metropolitan Area. J Womens Health. 2010;19(9):1675–81.CrossRef Lopez-de-Andres A, Martin-Lopez R, Hernandez-Barrera V, Carrasco-Garrido P, Gil-de-Miguel A, Pena MMEY, et al. Predictors of breast and cervical Cancer screening in a Spanish Metropolitan Area. J Womens Health. 2010;19(9):1675–81.CrossRef
58.
go back to reference Schoueri-Mychasiw N, McDonald PW. Factors Associated with Underscreening for Cervical Cancer among women in Canada. Asian Pac J Cancer P. 2013;14(11):6445–50.CrossRef Schoueri-Mychasiw N, McDonald PW. Factors Associated with Underscreening for Cervical Cancer among women in Canada. Asian Pac J Cancer P. 2013;14(11):6445–50.CrossRef
59.
go back to reference Bussiere C, Sicsic J, Pelletier-Fleury N. The effects of obesity and mobility disability in Access to breast and cervical Cancer screening in France: results from the National Health and Disability Survey. PLoS ONE. 2014;9(8). Bussiere C, Sicsic J, Pelletier-Fleury N. The effects of obesity and mobility disability in Access to breast and cervical Cancer screening in France: results from the National Health and Disability Survey. PLoS ONE. 2014;9(8).
60.
go back to reference Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol. 2014;38(2):174–80.PubMedCrossRef Kristensson JH, Sander BB, von Euler-Chelpin M, Lynge E. Predictors of non-participation in cervical screening in Denmark. Cancer Epidemiol. 2014;38(2):174–80.PubMedCrossRef
61.
go back to reference Virtanen A, Anttila A, Luostarinen T, Malila N, Nieminen P. Improving cervical cancer screening attendance in Finland. Int J Cancer. 2015;136(6):E677–E84.PubMedCrossRef Virtanen A, Anttila A, Luostarinen T, Malila N, Nieminen P. Improving cervical cancer screening attendance in Finland. Int J Cancer. 2015;136(6):E677–E84.PubMedCrossRef
62.
go back to reference Leinonen MK, Campbell S, Klungsoyr O, Lonnberg S, Hansen BT, Nygard M. Personal and provider level factors influence participation to cervical cancer screening: a retrospective register-based study of 1.3 million women in Norway. Prev Med. 2017;94:31–9.PubMedCrossRef Leinonen MK, Campbell S, Klungsoyr O, Lonnberg S, Hansen BT, Nygard M. Personal and provider level factors influence participation to cervical cancer screening: a retrospective register-based study of 1.3 million women in Norway. Prev Med. 2017;94:31–9.PubMedCrossRef
63.
go back to reference Harder E, Juul KE, Jensen SM, Thomsen LT, Frederiksen K, Kjaer SK. Factors associated with non-participation in cervical cancer screening - A nationwide study of nearly half a million women in Denmark. Prev Med. 2018;111:94–100.PubMedCrossRef Harder E, Juul KE, Jensen SM, Thomsen LT, Frederiksen K, Kjaer SK. Factors associated with non-participation in cervical cancer screening - A nationwide study of nearly half a million women in Denmark. Prev Med. 2018;111:94–100.PubMedCrossRef
64.
go back to reference Rodvall Y, Kemetli L, Tishelman C, Tornberg S. Factors related to participation in a cervical cancer screening programme in urban Sweden. Eur J Cancer Prev. 2005;14(5):459–66.PubMedCrossRef Rodvall Y, Kemetli L, Tishelman C, Tornberg S. Factors related to participation in a cervical cancer screening programme in urban Sweden. Eur J Cancer Prev. 2005;14(5):459–66.PubMedCrossRef
65.
go back to reference Azerkan F, Sparen P, Sandin S, Tillgren P, Faxelid E, Zendehdel K. Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer. 2012;130(4):937–47.PubMedCrossRef Azerkan F, Sparen P, Sandin S, Tillgren P, Faxelid E, Zendehdel K. Cervical screening participation and risk among Swedish-born and immigrant women in Sweden. Int J Cancer. 2012;130(4):937–47.PubMedCrossRef
66.
go back to reference Marlow LAV, Chorley AJ, Haddrell J, Ferrer R, Waller J. Understanding the heterogeneity of cervical cancer screening non-participants: data from a national sample of British women. Eur J Cancer. 2017;80:30–8.PubMedPubMedCentralCrossRef Marlow LAV, Chorley AJ, Haddrell J, Ferrer R, Waller J. Understanding the heterogeneity of cervical cancer screening non-participants: data from a national sample of British women. Eur J Cancer. 2017;80:30–8.PubMedPubMedCentralCrossRef
67.
go back to reference Moser K, Patnick J, Beral V. Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data. Brit Med J. 2009;338. Moser K, Patnick J, Beral V. Inequalities in reported use of breast and cervical screening in Great Britain: analysis of cross sectional survey data. Brit Med J. 2009;338.
68.
go back to reference Massat NJ, Douglas E, Waller J, Wardle J, Duffy SW. Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. Bmj Open. 2015;5(7). Massat NJ, Douglas E, Waller J, Wardle J, Duffy SW. Variation in cervical and breast cancer screening coverage in England: a cross-sectional analysis to characterise districts with atypical behaviour. Bmj Open. 2015;5(7).
69.
go back to reference Fernandez de Casadevante V, Cantarero-Arevalo L, Gil Cuesta J, Valentiner-Branth P. Ethnic background and human papillomavirus vaccine uptake in Denmark: a countrywide retrospective cohort study including 274,154 women aged 19–28 years. Papillomavirus Res. 2016;2:78–84.PubMedPubMedCentralCrossRef Fernandez de Casadevante V, Cantarero-Arevalo L, Gil Cuesta J, Valentiner-Branth P. Ethnic background and human papillomavirus vaccine uptake in Denmark: a countrywide retrospective cohort study including 274,154 women aged 19–28 years. Papillomavirus Res. 2016;2:78–84.PubMedPubMedCentralCrossRef
70.
go back to reference Hertzum-Larsen R, Kjaer SK, Frederiksen K, Thomsen LT. Participation in cervical cancer screening among immigrants and Danish-born women in Denmark. Prev Med. 2019;123:55–64.PubMedCrossRef Hertzum-Larsen R, Kjaer SK, Frederiksen K, Thomsen LT. Participation in cervical cancer screening among immigrants and Danish-born women in Denmark. Prev Med. 2019;123:55–64.PubMedCrossRef
71.
go back to reference de Casadevante VF, Cuesta JG, Cantarero-Arevalo L. Determinants in the uptake of the human papillomavirus vaccine: a systematic review based on European studies. Front Oncol. 2015;5. de Casadevante VF, Cuesta JG, Cantarero-Arevalo L. Determinants in the uptake of the human papillomavirus vaccine: a systematic review based on European studies. Front Oncol. 2015;5.
72.
go back to reference Badre-Esfahani S, Larsen MB, Seibaek L, Petersen LK, Blaakaer J, Andersen B. Low attendance by non-native women to human papillomavirus vaccination and cervical cancer screening - A Danish nationwide register-based cohort study. Prev Med Rep. 2020;19:101106.PubMedPubMedCentralCrossRef Badre-Esfahani S, Larsen MB, Seibaek L, Petersen LK, Blaakaer J, Andersen B. Low attendance by non-native women to human papillomavirus vaccination and cervical cancer screening - A Danish nationwide register-based cohort study. Prev Med Rep. 2020;19:101106.PubMedPubMedCentralCrossRef
73.
go back to reference Lynge E, Clausen LB, Guignard R, Poll P. What happens when organization of cervical cancer screening is delayed or stopped? J Med Screen. 2006;13(1):41–6.PubMedCrossRef Lynge E, Clausen LB, Guignard R, Poll P. What happens when organization of cervical cancer screening is delayed or stopped? J Med Screen. 2006;13(1):41–6.PubMedCrossRef
74.
go back to reference Hope KA, Moss E, Redman CWE, Sherman SM. Psycho-social influences upon older women’s decision to attend cervical screening: a review of current evidence. Prev Med. 2017;101:60–6.PubMedCrossRef Hope KA, Moss E, Redman CWE, Sherman SM. Psycho-social influences upon older women’s decision to attend cervical screening: a review of current evidence. Prev Med. 2017;101:60–6.PubMedCrossRef
75.
go back to reference Waller J, Jackowska M, Marlow L, Wardle J. Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study. Bjog-Int J Obstet Gy. 2012;119(1):26–32.CrossRef Waller J, Jackowska M, Marlow L, Wardle J. Exploring age differences in reasons for nonattendance for cervical screening: a qualitative study. Bjog-Int J Obstet Gy. 2012;119(1):26–32.CrossRef
76.
go back to reference Marlow L, McBride E, Varnes L, Waller J. Barriers to cervical screening among older women from hard-to-reach groups: a qualitative study in England. Bmc Womens Health. 2019;19. Marlow L, McBride E, Varnes L, Waller J. Barriers to cervical screening among older women from hard-to-reach groups: a qualitative study in England. Bmc Womens Health. 2019;19.
77.
go back to reference Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015;51(16):2375–85.PubMedCrossRef Verdoodt F, Jentschke M, Hillemanns P, Racey CS, Snijders PJF, Arbyn M. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: a systematic review and meta-analysis of randomised trials. Eur J Cancer. 2015;51(16):2375–85.PubMedCrossRef
78.
go back to reference Burger EA, Sy S, Nygard M, Kim JJ. The cost-effectiveness of cervical self-sampling to Improve Routine Cervical Cancer Screening: the importance of Respondent Screening History and Compliance. Cancer Epidem Biomar. 2017;26(1):95–103.CrossRef Burger EA, Sy S, Nygard M, Kim JJ. The cost-effectiveness of cervical self-sampling to Improve Routine Cervical Cancer Screening: the importance of Respondent Screening History and Compliance. Cancer Epidem Biomar. 2017;26(1):95–103.CrossRef
79.
go back to reference Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. HPV self-sampling in cervical cancer screening: the effect of different invitation strategies in various socioeconomic groups - a randomized controlled trial. Clin Epidemiol. 2018;10:1027–36.PubMedPubMedCentralCrossRef Tranberg M, Bech BH, Blaakaer J, Jensen JS, Svanholm H, Andersen B. HPV self-sampling in cervical cancer screening: the effect of different invitation strategies in various socioeconomic groups - a randomized controlled trial. Clin Epidemiol. 2018;10:1027–36.PubMedPubMedCentralCrossRef
80.
go back to reference Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD)2011. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the US Preventive Services Task Force. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Rockville (MD)2011.
81.
go back to reference Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med. 2018;114:188–92.PubMedCrossRef Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med. 2018;114:188–92.PubMedCrossRef
82.
go back to reference Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120(13):2032–8.PubMedCrossRef Rositch AF, Nowak RG, Gravitt PE. Increased age and race-specific incidence of cervical cancer after correction for hysterectomy prevalence in the United States from 2000 to 2009. Cancer. 2014;120(13):2032–8.PubMedCrossRef
83.
go back to reference Lam JU, Lynge E, Njor SH, Rebolj M. Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol. 2015;54(8):1136–43.PubMedCrossRef Lam JU, Lynge E, Njor SH, Rebolj M. Hysterectomy and its impact on the calculated incidence of cervical cancer and screening coverage in Denmark. Acta Oncol. 2015;54(8):1136–43.PubMedCrossRef
84.
go back to reference Stang A. Impact of hysterectomy on the age-specific incidence of cervical and uterine cancer in Germany and other countries. Eur J Public Health. 2013;23(5):879–83.PubMedCrossRef Stang A. Impact of hysterectomy on the age-specific incidence of cervical and uterine cancer in Germany and other countries. Eur J Public Health. 2013;23(5):879–83.PubMedCrossRef
85.
go back to reference Stang A, Hawk H, Knowlton R, Gershman ST, Kuss O. Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. Ann Epidemiol. 2014;24(11):849–54.PubMedCrossRef Stang A, Hawk H, Knowlton R, Gershman ST, Kuss O. Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. Ann Epidemiol. 2014;24(11):849–54.PubMedCrossRef
86.
go back to reference Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953–2010. Br J Cancer. 2004;90(9):1756–9.PubMedPubMedCentralCrossRef Luoto R, Raitanen J, Pukkala E, Anttila A. Effect of hysterectomy on incidence trends of endometrial and cervical cancer in Finland 1953–2010. Br J Cancer. 2004;90(9):1756–9.PubMedPubMedCentralCrossRef
87.
go back to reference White MC, Shoemaker ML, Benard VB. Cervical Cancer screening and incidence by Age: Unmet needs Near and after the stopping age for screening. Am J Prev Med. 2017;53(3):392–5.PubMedPubMedCentralCrossRef White MC, Shoemaker ML, Benard VB. Cervical Cancer screening and incidence by Age: Unmet needs Near and after the stopping age for screening. Am J Prev Med. 2017;53(3):392–5.PubMedPubMedCentralCrossRef
88.
go back to reference Rosenblatt KA, Osterbur EF, Douglas JA. Case-control study of cervical cancer and gynecologic screening: a SEER-Medicare analysis. Gynecol Oncol. 2016;142(3):395–400.PubMedCrossRef Rosenblatt KA, Osterbur EF, Douglas JA. Case-control study of cervical cancer and gynecologic screening: a SEER-Medicare analysis. Gynecol Oncol. 2016;142(3):395–400.PubMedCrossRef
89.
go back to reference Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044–50.PubMedCrossRef Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044–50.PubMedCrossRef
Metadata
Title
Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women
Authors
Sara Bønløkke
Jan Blaakær
Torben Steiniche
Maria Iachina
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-11994-4

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine